Gregory I. Frost, Ph.D., was the CEO of Halozyme Therapeutics, a biotechnology company he co-founded in 1999. Dr. Frost took the helm as CEO on December 2, 2010, after serving in other executive roles within the company, including Vice President...
Gregory I. Frost, Ph.D., was the CEO of Halozyme Therapeutics, a biotechnology company he co-founded in 1999. Dr. Frost took the helm as CEO on December 2, 2010, after serving in other executive roles within the company, including Vice President and Chief Scientific Officer. Under his leadership, Halozyme focused on developing and advancing multiple drug products, aiming to enhance treatment for various diseases. His tenure saw significant resource allocation towards research and development, promoting strategic partnerships to expand the company’s reach. A notable point in Dr. Frost's career was his departure from Halozyme in early 2014, which marked a transition in company leadership. During his time, he was involved in plans to optimize executive compensation, tying it directly to company performance metrics, which indicates a clear focus on aligning executive goals with shareholder interests. One interesting moment was the considerable insider trading fluctuations in Halozyme’s stock price during his leadership. Dr. Frost's experience and focus on performance shaped the company's strategies during critical years in the market.